Biochemical effects in women following one year's exposure to a new triphasic contraceptive--II. coagulation profiles.
1. Coagulation variables were determined in 14 contraceptive nonusers and 25 prior contraceptive users at 3, 6, and 12 months' exposure to a new oral form of progestin. 2. Overall hemostasis was unaffected, as was the intrinsic pathway. 3. Changes were noted in several vitamin-K dependent factors along with a marked decrease in fibrinogen. 4. Protein C antigen (a coagulation inhibitor), was elevated. 5. This new triphasic contraceptive appears to have a minimal influence on thrombosis while activating antithrombotic protein C. The data suggest a favorable hematologic response to this contraceptive.
Lox
C D
CD
Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Lubbock 79430, USA.
D000328:Adult; D001779:Blood Coagulation Factors / Q000032:analysis*; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology; D003279:Contraceptives, Oral, Sequential / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000031:analogs & derivatives / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology; D011486:Protein C / Q000032:analysis; D016387:Women's Health
D001779:Blood Coagulation Factors; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D003279:Contraceptives, Oral, Sequential; D011372:Progestins; D011486:Protein C; D009644:Norgestrel; D004997:Ethinyl Estradiol; C017576:norgestimate